Peptide·plain sequence-like

ATLPC0018201

AGCKNFFWKTFTSC

Compare in workbench Download release API JSON

Length
14 aa
Monoisotopic mass
1638.7 Da
Net charge @ pH 7.4
2.00
Isoelectric point
8.82
GRAVY
0.029

Coveragecounts only · not riskATLPC0018201

Measurements
14
Endpoints
2
Domains
2/5
Products
—

No matrix stability evidence
13 clearance measurements
No immunogenicity context
2 liability motifs

Jump to domain

Open the matching evidence section below

All evidence index · 14

Exposure / Absorption

No evidence

Distribution / Barrier

1 measurement

Metabolic & Proteolytic Stability

No evidence

Excretion / Persistence

13 measurements

Toxicity / Safety

No evidence

Sequence & molecular identity

1 forms

Reviewed sequence, peptidoform forms, chemical representation, 3D references, and covalent topology used to interpret this peptide identity.

Sequence & peptidoform

Identity summaryCanonical sequence only

Identity status: Canonical sequence only
Residues: 14
Peptidoform features: 0
Documented molecular forms: 1
Representations: 2

Documented molecular forms1 form linked to this peptide identity

Form	Topology	Modifications	Connections	Representations	Measurements
ATLPF0019896	—	—	—	Notation only	1

Residue view

Residue display

14 residues

A1G2C3K4N5F6F7W8K9T10F11T12S13C14

Secondary structureα-helix (H)β-strand (E)coil (C)

Side-chain classNonpolarPolarBasic (+)Acidic (−)Modified

Soft tints mark standard side-chain classes for scanning. Primary emphasis is reserved for reported modifications, termini, secondary-structure tracks, and topology links.

Peptidoform features

Features are shown only when a reported notation or topology record supports them.

No terminal modification, residue-level marker, disulfide, staple, coordination, or other topology signal is currently available.

Structure & chemistry

Chemical representationsequence / HELM only

Representation class

How the current release can interpret this identity chemically.

plain sequence-like

Parent-residue sequence

Residue string used for positional interpretation when available.

AGCKNFFWKTFTSC

HELM

Polymer notation for modified peptide representation when available.

Not available

SMILES

Chemical graph string used for atom-level 2D depiction when available.

Not available

No atom-level graph

A reviewed SMILES is required before a 2D molecular depiction can be shown. Sequence and HELM remain useful for identity interpretation, but they do not replace a chemical graph.

3D structure references1 reference

3D coordinates·PEPstrMOD predictionpredicted

PEPstrMOD prediction·reference selected·length 14 aa·confidence predicted

Link	Method	Confidence	Match
Open	PEPstrMOD model	predicted	14 aa

Covalent topology & modificationsnone

Exact topology not established

No reviewed form-level topology or residue-level connection annotation is attached to this peptide in the current release. This is not evidence that every molecular form is linear or unmodified.

Physicochemical profile

4 descriptors

Computed sequence-derived descriptors and any measured physicochemical evidence such as lipophilicity. Computed values are interpretation aids, not experimental ADMET measurements.

Core descriptors14 aa · pI 8.8 · GRAVY 0.03

Length: 14 aa
Monoisotopic mass: 1638.73 Da
Average mass: 1639.91 Da
Net charge at pH 7.4: 2.00
Estimated pI: 8.82
GRAVY: 0.029
KD-positive residues: 42.9%
Aromatic residues: 28.6%

Developability interpretation

Ionization context: pH 7.4 separated from pI
Hydrophobicity balance: Leans hydrophobic
Amphipathic moment (μH): 1.05
Computation boundary: Standard-sequence only

Charge & residue composition

pH charge context

Modeled net charge across common formulation and assay pH checkpoints.

pH 2

2.98

pH 5

2.04

pH 6

2.00

pH 7.4

1.79

pH 9

-0.27

pH 12

-2.88

Residue-class composition

Grouped composition is often more interpretable than a long amino-acid list.

Basic (K,R,H)

2 · 14.3%

Polar uncharged (N,Q,S,T)

4 · 28.6%

Hydrophobic aliphatic (A,V,I,L,M)

1 · 7.1%

Aromatic (F,W,Y)

4 · 28.6%

Conformational / sulfur (G,P,C)

3 · 21.4%

Top residues

F321.4%C214.3%K214.3%T214.3%A17.1%N17.1%G17.1%S17.1%

Hydropathy & amphipathic windows

Hydropathy windows

Seven-residue sliding windows expose local patches hidden by whole-sequence GRAVY.

Most hydrophobic window

6-12

FFWKTFT

GRAVY 0.314

Most hydrophilic window

4-10

KNFFWKT

GRAVY -1.043

8 local hydropathy windows scanned. A local patch is context for solubility, adsorption, and membrane interaction review, not a standalone endpoint.

Amphipathic-window scan

Top alpha-helix hydrophobic-moment windows across 12, 15, 18, and 21 residues.

12 aa window

3-14

CKNFFWKTFTSC

μH 1.33 · charge 2.0

12 aa window

2-13

GCKNFFWKTFTS

μH 1.14 · charge 2.0

12 aa window

1-12

AGCKNFFWKTFT

μH 1.01 · charge 2.0

Sequence-liability cues

Sequence-liability notes

Motifs are review prompts for formulation or CMC interpretation; they are not degradation predictions.

Oxidation-sensitive residues

W, C · pos 3, 8, 14

Met, Trp, and Cys residues can merit formulation review for oxidation or covalent-state sensitivity.

Cys covalent complexity

C · pos 3, 14

Multiple cysteines can indicate disulfide or free-thiol interpretation requirements.

Alpha-helix amphipathic projection

Helical wheel · Edmundson projection

μ_H = 1.05100°/residue · 14 aa

Hydrophobic moment1.05

Mean K-D hydropathy0.03

Approx. net charge+2

Projection angle100° / residue

The pale sector marks the direction of the hydrophobic face inferred from μ_H. This is a projection assumption, not a measured fold.

HydrophobicAromaticPolarBasic +Acidic −Specialhydrophobic faceμ_H arrow → hydrophobic face

The projection assumes an α-helix conformation; a long μ_H arrow indicates an amphipathic helix, common in antimicrobial peptides.

Method notes

Charge model: side-chain pKa D 3.9, E 4.1, C 8.5, Y 10.1, H 6.5, K 10.8, R 12.5 with EMBOSS termini. pI is estimated by binary search on modeled net charge. Hydropathy uses Kyte-Doolittle values; hydrophobic moment follows the Eisenberg alpha-helix vector-sum convention. When the basis is a parent-residue sequence, modified chemistry is intentionally not inferred.

Computed developability descriptors

Deterministic descriptors computed from the reviewed sequence or chemical structure (RDKit), each anchored to a literature method. These are computed estimates for developability interpretation — not experimental measurements — and are validated against independent reference implementations.

Sequence-derived

Computed from the standard parent-residue sequence; protein-origin metrics defined at any length.

Aliphatic index

7.14

Instability index

30.6

At or below 40 — predicted stable in vitro.

Boman index

0.69 kcal/mol

Molar extinction coefficient (280 nm)

5,500 M⁻¹·cm⁻¹

A280 (1 g/L) ≈ 3.35 · 5,625 M⁻¹·cm⁻¹ with 1 disulfide

Structure-derived descriptors are not shown because this identity has no resolved chemical structure (SMILES). This is a known coverage gap for disulfide-rich and unresolved peptidoforms, not a computation error.

Distribution / Barrier

1 records

What is known about distribution, binding, permeability, or barrier crossing?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeBBB penetration

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

BBB penetration1 record · 0 matched-context · 1 as reported · 0 context only · 0 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	Observation source reported BBB observation	Interpret as reported	Not specified	Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked	Source record

Barrier and permeability assay context

PAMPA, Caco-2, MDCK/RRCK, and BBB findings are assay/model contexts under Distribution / Barrier. They should not be read as interchangeable measurements.

PAMPA

artificial membrane

Caco-2

cell monolayer

MDCK

cell monolayer

RRCK

cell monolayer

BBB

barrier evidence

Excretion / Persistence

13 records

What evidence describes clearance or persistence?

Evidence records

Complete canonical measurements and observations attached to this domain.

Endpoint scope

Formal ADMET endpoints represented for this peptide.

Matched-context analysis

Quantitative results that may be analysed only with scientifically compatible records.

Reported-result review

Qualitative, narrative, or review-first results interpreted in their source context.

Endpoints in scopeHalf Life

Evidence interpretation

Result type, analysis use, and source-check status are kept separate so a numerical value is not mistaken for a universally comparable result.

Eligible for matched-context analysis

Quantitative results whose endpoint and context must still be matched before analysis.

Interpret as reported

Qualitative, narrative, or review-first findings preserved in source context.

Supporting context only

Reference, label, clinical, or supporting context for interpretation.

Review before analysis

Records whose present structure does not establish a safe analysis role.

Evidence by endpoint

Rows are grouped by endpoint so value, assay context, interpretation layer, and reference can be checked in place.

Half Life13 records · 5 matched-context · 7 as reported · 0 context only · 1 review required

#	Value	Analysis use	Assay / model	Result context	Reference
1	systemic pk half life unspecified phase: 7.6 minutes 456 seconds	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked	Reference
2	systemic pk half life unspecified phase: 0.73 ±0.03 hours 2628 seconds	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked	Reference
3	systemic pk half life unspecified phase: 0.79 ±0.17 hours 2844 seconds	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked	Reference
4	systemic pk half life unspecified phase: 1.23 ±0.16 hours 4428 seconds	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked	Reference
5	10 minutes 600 seconds	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro · Source: Primary reference linked	Reference
6	8406 seconds	Interpret as reported	Radioimmunoassay · Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Brodmann Area tissues proteases · in vitro · Source: Primary reference linked	Reference
7	7788.000000000001 seconds	Interpret as reported	Radioimmunoassay · Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Hippucampul tissues proteases · in vitro · Source: Primary reference linked	Reference
8	4788 seconds	Interpret as reported	Radioimmunoassay · Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Hippucampul tissues proteases · in vitro · Source: Primary reference linked	Reference
9	circulating somatostatin half life: 2.4 minute 144 seconds	Use only explicitly reported fields	Intravenous infusion to cat plasma	Result: Reported point value · Molecular form: not reported · Dose/window: 1.7nmol · Time: 1 hour · cat blood protease · in vivo · Source: Reference not captured	Evidence context
10	circulating somatostatin half life: 1.0 ±0.2 minutes 60 seconds	Use only explicitly reported fields	Radioimmunoassay · dog · Blood plasma sample from five mongrel dogs	Result: Reported point value · Molecular form: not reported · Dose/window: 100ng · Time: 5 days · in vivo · Source: Reference not captured	Evidence context

1–10 / 13

Evidence landscape

14 records

Cross-domain evidence distribution and measurement-level detail; the domain modules above show evidence in context, and every row remains available for audit here.

Evidence landscape

A cross-domain view of evidence volume, scientifically permitted analysis use, and source traceability.

ADMET domain

Eligible when context matches

Interpret as reported

Supporting context only

Review before analysis

Exposure / Absorption

0 evidence records

Distribution / Barrier

1 evidence record

Metabolic & Proteolytic Stability

0 evidence records

Excretion / Persistence

13 evidence records

Toxicity / Safety

0 evidence records

Endpoint distribution

Top evidence-bearing endpoint questions.

Half Life

Blood Brain Barrier Penetration

Assay context

Broad context buckets, useful before comparing values.

In vivo / route

Matrix / stability

Unspecified

Traceability

Reference-link availability for measurement-level audit.

Linked reference

Not linked

All evidence index

Every evidence record remains available for audit and drilldown. Counts describe evidence volume, not confidence.

DomainAnalysis useReferenceSpeciesMatrix

#	ADMET domain	Endpoint	Reported value	Result type	Analysis use	Assay / model	Condition	Reference
1	Excretion / Persistence Persistence	Half Life	7,788 seconds	Reported point value	Interpret as reported	Radioimmunoassay · Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Dose/window: 50μM · Protease: Hippucampul tissues proteases · in vitro	Reference Primary reference linked
2	Excretion / Persistence Persistence	Half Life	8,406 seconds	Reported point value	Interpret as reported	Radioimmunoassay · Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Dose/window: 50μM · Protease: Brodmann Area tissues proteases · in vitro	Reference Primary reference linked
3	Excretion / Persistence Persistence	Half Life	1.0 ±0.2 minutes 60 seconds Result metric: CIRCULATING_SOMATOSTATIN_HALF_LIFE	Reported point value	Use only explicitly reported fields	Radioimmunoassay · dog · Blood plasma sample from five mongrel dogs	Time: 5 days · Dose/window: 100ng · in vivo	Evidence context Reference not captured
4	Excretion / Persistence Persistence	Half Life	7.6 minutes 456 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo	Reference Primary reference linked
5	Excretion / Persistence Persistence	Half Life	0.73 ±0.03 hours 2,628 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo	Reference Primary reference linked
6	Excretion / Persistence Persistence	Half Life	0.79 ±0.17 hours 2,844 seconds Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE	Reported point value	Eligible when experimental context matches	ELISA · rat · Rat plasma (Intravenous injection)	Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo	Reference Primary reference linked
7	Excretion / Persistence Persistence	Half Life	< 5 minutes < 300 seconds Result metric: CIRCULATING_SOMATOSTATIN_HALF_LIFE	Upper-bound measurement	Use only explicitly reported fields	rat · Rats plasma	Protease: Rats blood proteases · in vivo	Evidence context Reference not captured
8	Excretion / Persistence Persistence	Half Life	4,788 seconds	Reported point value	Interpret as reported	Radioimmunoassay · Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)	Dose/window: 50μM · Protease: Hippucampul tissues proteases · in vitro	Reference Primary reference linked
9	Excretion / Persistence Persistence	Half Life	10 minutes 600 seconds	Reported point value	Eligible when experimental context matches	HPLC and LC/ITMS · Bacterial strain B-9 cell culture	Time: Room Temperature · Dose/window: 1mg/mL · Protease: Hydolytic activity of bacterial strain B-9 · in vitro	Reference Primary reference linked
10	Excretion / Persistence Persistence	Half Life	27 hours 97,200 seconds	Reported point value	Review experimental context before comparison	Not specified	Not specified	Reference Primary reference linked

1–10 / 14

Identity & reference map

14 sources

Reference-level support for checking reported names, sequence notation, and peptide identity agreement.

Summary9 reference groups

Identity type: canonical sequence
Reported notation: 0
Reference groups: 9
Measurements: 14
ATL peptide ID: ATLPC0018201

Identity concordance

Exact reported notation

Reported sequence string matches the current peptide notation.

0 / 14

Parent-residue compatible

Reported notation differs, but resolves to the same parent-residue display.

0 / 14

Different notation

Reported notation does not resolve to the current display sequence.

0 / 14

Source sequence not captured

No source-specific sequence was captured for comparison; this is not interpreted as agreement or disagreement.

14 / 14

Reported sequence notation

No source-specific sequence notation has been captured in the current identity references.

Current identity

AGCKNFFWKTFTSC

Reported names

No distinct human-readable aliases are exposed.

Reference map9 reference groups

Reference map

Grouped by reference link, with endpoint scope and reported identity kept visible.

Reference	Supports	Reported identity	Records
Reference Open	Persistence Half Life	No reported alias	4 identity 4 evidence
Reference Open	Persistence Half Life	No reported alias	3 identity 3 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Reference Open	Persistence Half Life	No reported alias	1 identity 1 evidence
Source record Open	Distribution Blood Brain Barrier Penetration	No reported alias	1 identity 1 evidence
Evidence context Not linked	Persistence Half Life	No reported alias	1 identity 1 evidence
Evidence context Not linked	Persistence Half Life	No reported alias	1 identity 1 evidence
Evidence context Not linked	Persistence Half Life	No reported alias	1 identity 1 evidence
Evidence context Not linked	Persistence Half Life	No reported alias	1 identity 1 evidence

Data access & reproducibility

Stable record access, analysis-ready files, and scripted retrieval for reproducing this profile view.

Record scopePublic release

ATL peptide ID: ATLPC0018201
Identity type: canonical sequence
ADMET endpoints: 2
Evidence records: 14
Reference groups: 9
Release view: Public release

Data access

Structured peptide profile

JSON

Peptide-specific profile used by this page, including identity and evidence context.

Open JSON

Peptide catalogue

TSV

Complete frozen peptide table. Filter the ATL peptide ID column locally to isolate this record.

Download catalogue

Measurement catalogue

TSV

Complete frozen measurement table. Join or filter by ATL peptide ID for peptide-level analysis.

Download measurements

Programmatic access

The request returns the same structured peptide record used by this profile. The tabular downloads are complete frozen release tables and should be filtered locally by ATL peptide ID.

Open endpoint

GET /api/v1/peptides/ATLPC0018201

open

curl -sS 'https://admetatlas.scbdd.com/api/v1/peptides/ATLPC0018201' \
  -H 'accept: application/json' \
  -H 'X-Visibility: public_release'

Form

Topology

Modifications

Connections

Representations

Measurements

ATLPF0019896

—

Notation only

Link

Method

Confidence

Match

Open

PEPstrMOD model

predicted

14 aa

Value

Analysis use

Assay / model

Result context

Reference

Observation

source reported BBB observation

Interpret as reported

Not specified

Result: Qualitative or narrative result · Molecular form: not reported · Source: Primary reference linked

Source record

Value

Analysis use

Assay / model

Result context

Reference

systemic pk half life unspecified phase: 7.6 minutes

456 seconds

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked

Reference

systemic pk half life unspecified phase: 0.73 ±0.03 hours

2628 seconds

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked

Reference

systemic pk half life unspecified phase: 0.79 ±0.17 hours

2844 seconds

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked

Reference

systemic pk half life unspecified phase: 1.23 ±0.16 hours

4428 seconds

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1.8 mg/ml · Rat blood proteases · in vivo · Source: Primary reference linked

Reference

10 minutes

600 seconds

Eligible when experimental context matches

HPLC and LC/ITMS · Bacterial strain B-9 cell culture

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 1mg/mL · Time: Room Temperature · Hydolytic activity of bacterial strain B-9 · in vitro · Source: Primary reference linked

Reference

8406 seconds

Interpret as reported

Radioimmunoassay · Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Brodmann Area tissues proteases · in vitro · Source: Primary reference linked

Reference

7788.000000000001 seconds

Interpret as reported

Radioimmunoassay · Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Hippucampul tissues proteases · in vitro · Source: Primary reference linked

Reference

4788 seconds

Interpret as reported

Radioimmunoassay · Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Result: Reported point value · Molecular form: ATLPF0041064 · Dose/window: 50μM · Hippucampul tissues proteases · in vitro · Source: Primary reference linked

Reference

circulating somatostatin half life: 2.4 minute

144 seconds

Use only explicitly reported fields

Intravenous infusion to cat plasma

Result: Reported point value · Molecular form: not reported · Dose/window: 1.7nmol · Time: 1 hour · cat blood protease · in vivo · Source: Reference not captured

Evidence context

circulating somatostatin half life: 1.0 ±0.2 minutes

60 seconds

Use only explicitly reported fields

Radioimmunoassay · dog · Blood plasma sample from five mongrel dogs

Result: Reported point value · Molecular form: not reported · Dose/window: 100ng · Time: 5 days · in vivo · Source: Reference not captured

Evidence context

ADMET domain

Endpoint

Reported value

Result type

Analysis use

Assay / model

Condition

Reference

Excretion / Persistence

Persistence

Half Life

7,788 seconds

Reported point value

Interpret as reported

Radioimmunoassay · Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Dose/window: 50μM · Protease: Hippucampul tissues proteases · in vitro

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

8,406 seconds

Reported point value

Interpret as reported

Radioimmunoassay · Brodmann Area tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Dose/window: 50μM · Protease: Brodmann Area tissues proteases · in vitro

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

1.0 ±0.2 minutes

60 seconds

Result metric: CIRCULATING_SOMATOSTATIN_HALF_LIFE

Reported point value

Use only explicitly reported fields

Radioimmunoassay · dog · Blood plasma sample from five mongrel dogs

Time: 5 days · Dose/window: 100ng · in vivo

Evidence context

Reference not captured

Excretion / Persistence

Persistence

Half Life

7.6 minutes

456 seconds

Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE

Reported point value

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

0.73 ±0.03 hours

2,628 seconds

Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE

Reported point value

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

0.79 ±0.17 hours

2,844 seconds

Result metric: SYSTEMIC_PK_HALF_LIFE_UNSPECIFIED_PHASE

Reported point value

Eligible when experimental context matches

ELISA · rat · Rat plasma (Intravenous injection)

Dose/window: 1.8 mg/ml · Protease: Rat blood proteases · in vivo

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

< 5 minutes

< 300 seconds

Result metric: CIRCULATING_SOMATOSTATIN_HALF_LIFE

Upper-bound measurement

Use only explicitly reported fields

rat · Rats plasma

Protease: Rats blood proteases · in vivo

Evidence context

Reference not captured

Excretion / Persistence

Persistence

Half Life

4,788 seconds

Reported point value

Interpret as reported

Radioimmunoassay · Posterior Hippucampus tissues of brain of SDAT(Alzheimer's Disease Brain Bank, Bronx, NY)

Dose/window: 50μM · Protease: Hippucampul tissues proteases · in vitro

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

10 minutes

600 seconds

Reported point value

Eligible when experimental context matches

HPLC and LC/ITMS · Bacterial strain B-9 cell culture

Time: Room Temperature · Dose/window: 1mg/mL · Protease: Hydolytic activity of bacterial strain B-9 · in vitro

Reference

Primary reference linked

Excretion / Persistence

Persistence

Half Life

27 hours

97,200 seconds

Reported point value

Review experimental context before comparison

Not specified

Reference

Primary reference linked

Reference

Supports

Reported identity

Records

Reference

Open

Persistence

Half Life

No reported alias

4 identity

4 evidence

Reference

Open

Persistence

Half Life

No reported alias

3 identity

3 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Reference

Open

Persistence

Half Life

No reported alias

1 identity

1 evidence

Source record

Open

Distribution

Blood Brain Barrier Penetration

No reported alias

1 identity

1 evidence

Evidence context

Not linked

Persistence

Half Life

No reported alias

1 identity

1 evidence

Evidence context

Not linked

Persistence

Half Life

No reported alias

1 identity

1 evidence

Evidence context

Not linked

Persistence

Half Life

No reported alias

1 identity

1 evidence

Evidence context

Not linked

Persistence

Half Life

No reported alias

1 identity

1 evidence

ATLPC0018201

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue

ATLPC0018201

Sequence & molecular identity

Sequence & peptidoform

Structure & chemistry

Physicochemical profile

Computed developability descriptors

Distribution / Barrier

Excretion / Persistence

Evidence landscape

Product context

Identity & reference map

Data access & reproducibility

Structured peptide profile

Peptide catalogue

Measurement catalogue